Contribution of new immunoglobulin-derived biomarkers in plasma cell dyscrasias and lymphoproliferative disorders
Contribution of new immunoglobulin-derived biomarkers in plasma cell dyscrasias and lymphoproliferative disorders作者机构：Haematology Section of 1~(st) Department of Propaedeutic Internal Medicine Athens Medical SchoolLaikon University Hospital 11527 Athens Greece The Binding Site Group Ltd. BirminghamB151QT United Kingdom
出 版 物：《World Journal of Hematology》 (世界血液学杂志)
年 卷 期：2013年第2卷第2期
页 面：6-12页
学科分类：10[医学]
主 题：Immunoglobulin quantification FreeliteTM HevyliteTM Diagnosis Monitoring Prognosis
摘 要：New assays for serum immunoglobulin(Ig) free and heavy chain quantification were developed for routine clinical practice. Serum free light chain(s FLC) assay was shown to improve detection, management and prognostication in all plasma cell dyscrasias. More precisely, s FLC measurements proved to be prognostic for the progression of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma(MM), became markers of response and survival in amyloid light-chain amyloidosis and contributed to accurate follow-up of patients with light chain and non secretory MM. In addition, s FLC and they ratio(s FLCR) were shown useful for the prognosis and monitoring of intact Ig myeloma; their evaluation was incorporated in the new uniform response criteria. s FLC or s FLCR were also observed abnormal in B-cell non-Hodgkin lymphoma/chronic lymphocytic leukemia(CLL). Moreover, increased s FLC levels, summated s FLC or abnormal s FLCR predict shorter overall survival in early-stage CLL while increased s FLC constituted an independent, adverseprognostic factor for event-free and overall survival in diffuse large B-cell lymphoma and Waldenstrom s macroglobulinemia. Clinical applications of heavy Ig chain separately(HLC) measurements are more recent and mainly concern MM in which HLC deriving ratios correlated with parameters of disease activity and constituted an adverse survival marker.
维普期刊数据库